镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在前列腺癌主动监测试验(PASPoRT)中的应用
单中心前瞻性队列研究纳入141例新诊断并开始主动监测的前列腺癌患者,在标准诊断基础上加做[68Ga]-PSMA PET/CT并对SUVmax≥4且既往未活检的PSMA病灶靶向活检,13例(9%)发现升级,需扫描人数为11(95%CI 6-18)。
要点
- PSMA PET/CT联合靶向活检在141例主动监测患者中检出13例(9%)病理升级。
- 每检出1例升级需扫描11例患者(95%CI 6-18),研究设计把握度针对需扫描人数10。
- MRI阴性(PI-RADS 1-2)患者中PSMA PET/CT及靶向活检发现升级最常见。
核心结论
- PSMA PET/CT可进一步改善经MRI和靶向活检诊断后的前列腺癌患者风险分层及主动监测选择。
研究设计与样本
- 单中心前瞻性队列研究(NL69880.100.19),纳入141例新诊断并开始主动监测的前列腺癌患者,诊断时均接受活检前MRI及针对可见病灶的靶向活检,并额外接受[68Ga]-PSMA PET/CT及对SUVmax≥4且既往活检未覆盖的所有PSMA病灶的靶向活检。
主要发现
- 45例(32%)患者接受了额外PSMA靶向活检,13例(9%)检出升级:9例GG 2、2例GG 3、1例GG 4、1例GG 5。
- 需扫描人数为11(95%CI 6-18)。
- 在所有参与者中,PSMA PET/CT及靶向活检在MRI阴性(PI-RADS 1-2)患者中检出升级最频繁。
- 在接受额外PSMA靶向活检的患者中,升级最常发现于前列腺特异性抗原密度较高且MRI阴性的患者。
局限性
- 缺乏与标准重复活检的比较。
- MRI无中心化审阅。
- 可能存在活检采样误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of clinical parameters, including prebiopsy magnetic resonance imaging (MRI), to decide between active surveillance (AS) and active therapy for prostate cancer (PCa) leads to imperfect selection. Additional prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging may improve risk stratification. OBJECTIVE: To study risk stratification and patient selection for AS with the addition of PSMA PET/CT to standard practice. DESIGN, SETTING, AND PARTICIPANTS: A single-centre prospective cohort study (NL69880.100.19) enrolled patients recently diagnosed with PCa who started AS. At diagnosis, all participants had undergone prebiopsy MRI and targeted biopsy for visualised lesions. Patients underwent an additional [68Ga]-PSMA PET/CT and targeted biopsy of all PSMA lesions with a maximum standardised uptake value (SUVmax) of ≥4 not covered by previous biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the number needed to scan (NNS) to detect one patient with upgrading. The study was powered to detect an NNS of 10. Regarding secondary outcomes, univariate logistic regressions analyses were performed on all patients and on the patients who received additional PSMA targeted biopsies on the likelihood of upgrading. RESULTS AND LIMITATIONS: A total of 141 patients were included. Additional PSMA targeted biopsies were performed in 45 (32%) patients. In 13 (9%) patients, upgrading was detected: nine grade group (GG) 2, two GG 3, one GG 4, and one GG 5. The NNS was 11 (95% confidence interval 6-18). Of all participants, PSMA PET/CT and targeted biopsies yielded upgrading most frequently in patients with negative MRI (Prostate Imaging Reporting and Data System [PI-RADS] 1-2). Of patients who received additional PSMA targeted biopsies, upgrading was most frequently found in those with higher prostate-specific antigen density and negative MRI. Limitations included the lack of comparison with standard repeat biopsy, no central review of MRI, and possibility of biopsy sampling error. CONCLUSIONS: PSMA PET/CT can further improve PCa risk stratification and selection for AS patients diagnosed after MRI and targeted biopsies. PATIENT SUMMARY: Prostate-specific membrane antigen positron emission tomography/computed tomography and additional targeted prostate biopsies can identify more aggressive prostate cancer cases previously missed in patients recently started with expectant management for favourable-risk prostate cancer.
引用
- Heetman JG, Lavalaye J, Polm PD, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT). Eur Urol Oncol. 2023. PMID: 37296065. doi:10.1016/j.euo.2023.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。